Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then limitations. That order makes critique coherent.
0 likes 2y
Evidence · Journal club · continued
Journal club: FLOW and the renal composite, component by component posts 91–92
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
h.eriksen, post #4: STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially larger than anything previously achieved pharmacologically. Go to post
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
This topic was referenced in
- Journal club: what we got wrong in an earlier sessionEvidence › Journal club · 125 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: indirect comparison between two programmes, defended and attacked — one year on
Posting this under the heading it deserves: Journal club: indirect comparison between two programmes, defended and attacked — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N…
|
+45 | 50 | 3k | 9mo |
|
[2026 update] Journal club: what we got wrong in an earlier session
Journal club: what we got wrong in an earlier session — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…
|
+5 | 9 | 4.2k | 1d |
|
Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021) with SURMOUNT-OSA (…
|
+116 | 120 | 23k | 3mo |
|
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Comparing STEP 2 ( Lancet , 2021) with SURPASS-2 ( N Engl J Med ,…
|
+70 | 76 | 4.8k | 15h |
|
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SELECT ( N…
|
4 | 1.3k | 1mo |
Related topics — sharing the tags randomised trial, estimand, risk of bias
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Open-label extensions: what survives and what does not
Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with PIONEER 6 ( N Engl J Med ,…
|
4 | 22k | 3mo | |
|
Interim analyses and stopping rules — does this still hold?
Interim analyses and stopping rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with SURMOUNT-4 (…
|
+30 | 34 | 29k | 13mo |
|
Coming back to: Prediction intervals and why they are more honest than confidence intervals
Prediction intervals and why they are more honest than confidence intervals Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024)…
|
2 | 65 | 22mo | |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…
|
+128 | 145 | 3k | 4mo |
|
Conference abstracts as evidence: the weakest common citation
On the subject in the title: Conference abstracts as evidence: the weakest common citation Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
+1 | 5 | 2k | 9mo |